Synexa Life Sciences Expands Bioanalysis Capabilities with the Acquisition of Alderley Analytical

The image portrays a team of professionals from Alderley Analytical, engaged in a discussion in a relaxed, informal setting. The group is seated across from each other on comfortable, modern furniture, fostering a sense of open dialogue and collaboration. The presence of a plant hanging overhead and the natural light from the windows contribute to a warm and inviting atmosphere, emphasizing a work environment that values communication and team cohesion. This scene likely represents a moment of strategic planning, idea sharing, or team building, illustrating the company's commitment to fostering a collaborative and supportive workplace culture. The diverse team, shown in professional attire, reflects a range of roles and expertise within Alderley Analytical, highlighting the multidisciplinary approach the company employs to achieve excellence in bioanalytical services. This image effectively conveys the human element of Alderley Analytical, showcasing the professionals behind the science and their collaborative efforts to drive innovation and maintain high standards in their field.

LEIDEN, THE NETHERLANDS, 3rd October 2024 – Synexa Life Sciences BV, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical, an independent bioanalytical Contract Research Organisation (CRO) based in Alderley, UK.

This strategic acquisition is a key step in Synexa’s ‘buy and build’ growth strategy, driven by the company’s vision to become ‘the scientific partner of choice for biomarker and bioanalytical solutions’.

Integrating Alderley Analytical’s advanced bioanalytical capabilities into Synexa Life Sciences’ established strengths in biomarker and bioanalytical assays—covering DNA, RNA, protein, cell, and tissue analysis—will significantly enhance the combined company’s service offerings. The acquisition will expand Synexa’s capacity and broaden its range of analytical platforms across LC-MS/MS, enabling Synexa to strengthen its comprehensive suite of bioanalytical services and deepen its scientific offering to customers.

“Acquiring Alderley Analytical is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and broadening our global reach. This integration will enable us to offer a more comprehensive range of services, such as Mass Spectrometry, and drive further innovation in biomarker and bioanalytical solutions. We are thrilled to welcome the Alderley team to Synexa and look forward to integrating our strengths.”– commented the CEO of Synexa Life Sciences, Emile Lens.

Paul Holme, CEO and Founder of Alderley Analytical, commented: “We are thrilled to join forces with Synexa Life Sciences. This acquisition represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”

About Synexa Life Sciences

Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and, ultimately, better management and treatment of human health.

Synexa Life Sciences is backed by Gilde Healthcare, a specialist healthcare Venture Capital firm based in the Netherlands.

About Alderley Analytical

Alderley Analytical is an independent Contract Research Organisation (CRO) specialising in bioanalytical services to support drug development through discovery, pre-clinical safety testing, and clinical development. As a GLP and GCP-accredited laboratory, Alderley Analytical offers regulatory compliance and method validation according to current guidelines, providing reliable and accurate bioanalytical results. 

Contact us now to learn more

Contact Us